ARID1A and ovarian cancer: Similarly, inhibition of the EZH2 methyltransferase subunit of the PRC2 complex in ARID1A-mutated ovarian cancer cells also results in a SL interaction related to PI3 kinase-AKT signaling (Bitler et al., 2015).